AMEX: NEP), announced today it is initiating supplemental clinical trials across five nations in Europe to demonstrate therapy effectiveness and treatment cost savings achieved through the use of its OLpur(TM) MD190 filter product in providing therapy for chronic End Stage
Renal Disease (ESRD).
Devoting our undivided attention to the ongoing completion of the Phase I clinical trials of the Wearable Kidney will allow us to ensure success in bringing to market a technology that will greatly alleviate the plight of hundreds of thousands of End Stage
Renal Disease human beings currently on dialysis, while reducing the enormous cost associated with keeping alive these unfortunate patients.
There are now two major studies indicating a measurable reduction in mortality for chronic End Stage
Renal Disease patients using hemodiafiltration (HDF) therapy instead of hemodialysis, which is currently the predominant therapy for patients in the U.
Treatment with NxStage System One is covered by Medicare just like all other hemodialysis treatments as part of the End Stage
Renal Disease (ESRD) program.
Nephros's OLpur(TM) HD190 is designed for use in a variety of End Stage
Renal Disease (ESRD) therapies, including hemodialysis (HD) and hemodiafiltration (HDF), and is labeled accordingly.
renal disease refers to irreversible kidney failure that requires dialysis or a kidney transplant.
Our research and development work on the OLpur H2H and MD filter technologies for End Stage
Renal Disease therapy provided us with the foundations for a proprietary multi-stage water filter that is cost effective, extremely reliable, and long-lasting.
SynCardia's vision to be the front-piece of end stage
heart failure is backed by a fantastic technology that addresses unmet needs, ambitious yet achievable goals, and an immensely talented and experienced upper management team," concludes Dr.
We continue to expand the distribution of our core technology for the treatment of End Stage
Renal Disease in Europe, as well as Japan, and have recently taken initial steps toward introducing our products in the United States.
GHI is among the insurance industry leaders who have recognized the tremendous need to address the debilitating effects of end stage
renal disease on its members, and is making the commitment to provide help and support.
The Wearable Kidney, for which the Company recently received its first patent, is designed to treat patients suffering from End Stage
Renal Disease by providing continuous dialysis from a device worn as a belt by the patient.
Daxor's BVA-100 will reside within the nuclear medicine department, and will be utilized in diagnosing blood volume derangements in various clinical conditions, but most specifically in patients with septic shock; following coronary artery by-pass surgery; and end stage
kidney dialysis patients.